Fulgent Genetics, Inc. (FLGT) research
Fulgent Genetics, Inc.- Sector
- Health Care
- Last price
- $21.48
- As of
Fulgent Genetics, Inc. (FLGT): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-30.
As of . Source: SEC EDGAR filings for FLGT. Method and limitations.
Share the FLGT intelligence card
See the full FLGT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for FLGT on one page. Preview it with sample data, then open it live with a free account.
Preview the FLGT dossierActive signals for FLGT
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +65% to FLGT (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 74% of FLGT (2026Q2)
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 58.0%, EPS $-0.58 vs $-0.3672 estimate
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 57% of FLGT (2026Q1)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 78% of FLGT (2026Q1)
FREE, NO ACCOUNT
Every signal on FLGT, as it fires
You are seeing 5 of 10 signals recorded on FLGT since 2026-05-29.
The five above landed across 3 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in FLGT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP 359664109 · 2026Q2 | $8.2M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 359664109 · 2026Q2 | $6.6M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 359664109 · 2026Q2 | $6M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 359664109 · 2026Q2 | $4.3M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 359664109 · 2026Q2 | $3.6M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, FLGT
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
FLGT against its peers
FLGT's operating margin of -28.2% ranks in the 17th percentile of 25 Health Care sub-industry peers, fiscal periods ending between 2025-08-31 and 2026-05-31.
| Metric | FLGT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 323M USD | 781M USD | 40 | 25 |
| Gross margin | 40.6% | 58.4% | 25 | 13 |
| Operating margin | -28.2% | -3.3% | 17 | 25 |
| Net margin | -18.8% | -6.7% | 29 | 25 |
| Return on equity | -5.4% | -10.0% | 54 | 24 |
| P / E | n/a | 46.7x | n/a | 7 |
Peers (25): ANGO, EHAB, SGHT, CERS, AHCO, VREX, CCRN, TALK, EVH, SLP, HSTM, BVS, CTEV, PRCT, TDOC, CSTL, IRMD, GDRX, STAA, TNDM, OMDA, USPH, PNTG, CNMD, AMN. Fiscal periods ending between 2025-08-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (FLGT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow FLGT on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to FLGT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.